Previous dengue or zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses
Memorias do Instituto Oswaldo Cruz, ISSN: 1678-8060, Vol: 114, Issue: 7, Page: e190098
2019
- 27Citations
- 1,922Usage
- 106Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations27
- Citation Indexes27
- 27
- CrossRef3
- Usage1,922
- Full Text Views1,750
- 1,750
- Abstract Views172
- 172
- Captures106
- Readers106
- 106
Article Description
BACKGROUND Dengue virus (DENV) has circulated in Brazil for over 30 years. During this time, one serotype has cyclically replaced the other, until recently, when all four distinct serotypes began to circulate together. Persistent circulation of DENV for long time periods makes sequential infections throughout a person’s life possible. After primary DENV infection, life-long immunity is developed for the infecting serotype. Since DENV and Zika virus (ZIKV) are antigenically similar, the possibility of cross-reactions has attracted attention and has been demonstrated in vitro. OBJECTIVE The aim of this study was to investigate whether immune-sera from DENV and ZIKV infected patients would cross-react in vitro with other Flaviviridae family members. METHODS Cross-reaction of the studied samples with yellow fever virus (YFV), West Nile virus (WNV), Rocio virus (ROCV), Saint Louis virus (SLEV) and Ilheus virus (ILHV) has been investigated by plaque reduction neutralisation test (PRNT) and the antibody-dependent enhancement (ADE) by f low-cytometry. FINDINGS Antibodies against ZIKV and DENV virus cross-reacted with other f laviviruses either neutralising or enhancing the infection. Thus, viral entrance into FcRFcɣRII-expressing cells were inf luenced by the cross-reactive antibodies. ZIKV or DENV immune sera enhanced cellular infection by WNV, ILHV, ROCV and SLEV. Finally, DENV immune sera presented higher neutralising activity for YFV and SLEV. While ZIKV immune sera neutralised WNV, ILHV and ROCV with high frequencies of positivity. MAIN CONCLUSIONS The co-circulation of those viruses in the same area represents a risk for the development of severe infections if they spread throughout the country. Successive f lavivirus infections may have an impact on disease pathogenesis, as well as on the development of safe vaccine strategies.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85070986037&origin=inward; http://dx.doi.org/10.1590/0074-02760190098; http://www.ncbi.nlm.nih.gov/pubmed/31411310; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762019000100341&tlng=en; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762019000100341&lng=en&tlng=en; http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0074-02762019000100341&lng=en&tlng=en; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762019000100341; http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0074-02762019000100341; https://dx.doi.org/10.1590/0074-02760190098; https://www.scielo.br/j/mioc/a/V47JkyBjmZ7qvNJCjs48nZf/?lang=en
FapUNIFESP (SciELO)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know